ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory marginal zone lymphoma.
In a joint conference event yesterday, cell therapy pioneer Carl June revealed unpublished results showing that in around 1,500 patients treated with CAR-T therapies, no cases of secondary malignancy could be definitively linked to the treatment.
The company’s U.S. sales have been boosted by persistently strong demand for Lenalidomide, a generic version of Bristol-Myers Squibb’s (BMY.N) blockbuster cancer drug Revlimid, which was launched in 2022.
“The APAC region reports the most asthma-related deaths. This underscores the urgent need for effective treatments and management strategies tailored to the unique challenges faced in the region. Addressing these challenges requires a multi-faceted approach, including enhanced patient education, early diagnosis, improved treatment accessibility, and adherence to therapies,” states GlobalData Analyst Sravani Meka.
The agency’s panel of independent advisers will on June 4 deliberate whether they should recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder, Lykos Therapeutics stated.
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and opposed proposals related to executive compensation, weeks after pushing for a board shakeup at the COVID-19 vaccine maker.